Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Notes Payables (2016 - 2021)

Sunshine Biopharma filings provide 8 years of Notes Payables readings, the most recent being $1.9 million for Q4 2021.

  • On a quarterly basis, Notes Payables rose 131.58% to $1.9 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.9 million, a 131.58% increase, with the full-year FY2021 number at $1.9 million, up 131.58% from a year prior.
  • Notes Payables hit $1.9 million in Q4 2021 for Sunshine Biopharma, up from $330000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.9 million in Q4 2021 to a low of $3915.0 in Q1 2018.
  • Median Notes Payables over the past 5 years was $265088.5 (2017), compared with a mean of $380557.2.
  • Biggest five-year swings in Notes Payables: plummeted 94.52% in 2018 and later soared 2678.95% in 2019.
  • Sunshine Biopharma's Notes Payables stood at $596577.0 in 2017, then fell by 29.65% to $419663.0 in 2018, then soared by 39.71% to $586307.0 in 2019, then soared by 39.94% to $820454.0 in 2020, then surged by 131.58% to $1.9 million in 2021.
  • The last three reported values for Notes Payables were $1.9 million (Q4 2021), $330000.0 (Q3 2021), and $330000.0 (Q2 2021) per Business Quant data.